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Resistance to anticancer drugs is widely observed in vitro and in cancer patients, but its preva-
lence is too high to be solely explained by the acquisition of mutations. Sharma et al. (2010) now 
report that dynamic chromatin modifications may be an independent route to drug resistance in 
cancer cells that can be reversed by epigenetic drugs.Drug resistance is the nightmare of every 
cancer patient receiving cytotoxic or tar-
geted therapy for disseminated cancer. 
Well-established mechanisms underpin 
the different routes to drug resistance 
in tumor cells, including drug export, 
augmented drug metabolism, and sec-
ondary mutations in the drug target or 
in parallel pathways (Redmond et al., 
2008). Cancer-initiating cells have also 
been proposed as potential culprits 
because of their capacity to escape 
from the effects of drug treatment by 
becoming quiescent (Frank et al., 2010; 
Peacock and Watkins, 2008). Heteroge-
neity, in general, enables organisms to 
adapt to changing environmental condi-
tions, constituting the basis of Darwinian 
selection. Genetic variability is the hard-
wired version of heterogeneity. However, 
heterogeneity also occurs within geneti-
cally identical populations. In bacteria, 
up to 1% of the population might show 
drug resistance that is caused not by 
genetic mechanisms (such as the acqui-
sition of plasmids encoding antibiotic 
resistance genes) but by mechanisms 
that reduce proliferation, a characteristic 
associated with a dormant, nondividing 
state. Bacteria exhibiting this character-
istic are called “persisters” (Lewis, 2007) 
and resemble cancer-initiating cells 
(Frank et al., 2010). But what determines 
this resistance state and how can it be 
overcome? In a provocative paper in this 
issue of Cell, Settleman and colleagues 
(Sharma et al., 2010) not only provide 
intriguing insights into how such resis-
tance mechanisms might operate but 
also suggest how they might be tackled 
and abolished.
These investigators exposed the 
PC9 non-small cell lung cancer cell 
line, carrying an activating mutation 18 Cell 141, April 2, 2010 ©2010 Elsevier Incin the epidermal growth factor recep-
tor (EGFR), to the drug erlotinib that 
abrogates EGFR signaling. Although 
this treatment (at a dose 50 times the 
IC50) killed nearly all PC9 parental cells, 
a small fraction of mostly nondividing 
cells (the drug-tolerant persisters) sur-
vived the treatment (Figure 1). Roughly 
20% of these cells reinitiated growth in 
the presence of erlotinib, becoming so-
called drug-tolerant expanded persist-
ers. This acquired resistance was not 
caused by genetic alterations known to 
confer resistance to erlotinib, including 
secondary mutations (such as T790M) 
in EGFR or ERBB3 (HER3) activation 
through amplification of the receptor 
tyrosine kinase MET (Engelman et al., 
2007). Rather, the acquired drug resis-
tance was due to a different chroma-
tin configuration in the drug-tolerant 
persisters present in the PC9 parental 
population. The drug-tolerant persist-
ers, comprising ?0.3% of the parental 
tumor cell population, all expressed 
CD133 and were enriched for CD24-
positive cells, markers preferentially 
expressed by stem cells. Interestingly, 
the drug-tolerant expanded persist-
ers, which arose from the quiescent 
drug-tolerant persister population by 
resuming proliferation in the presence 
of erlotinib, exhibited the marker het-
erogeneity of the parental PC9 cell line. 
This indicated that the “stem cell phe-
notype” of drug-tolerant persisters was 
only important for their survival during 
initial drug exposure. Cells surviving 
erlotinib exposure also showed cross-
resistance to the chemotherapeutic 
cisplatin. Notably, expanded single-cell 
clones from the parental PC9 cell line 
gave rise to drug-tolerant persisters 
and expanded persisters at frequencies .similar to the uncloned population, sup-
porting a mechanism of nonmutational 
heterogeneity. In line with this notion, 
continued culture of the drug-tolerant 
expanded persisters in the absence of 
erlotinib gave rise to drug-sensitive cells, 
although it required many passages 
to “unlock” the drug-tolerant state. A 
similar behavior was also observed for 
other tumor cell lines, indicating that 
many, if not all, tumor cells share this 
mechanism. This regained drug sensi-
tivity has a corollary in clinical practice 
and is described as the “re-treatment 
response,” the reacquisition of a drug 
response after a “drug holiday.”
To gain insight into the underlying 
mechanism of PC9 tumor cell drug 
resistance, Settleman and coworkers 
analyzed gene expression profiles of 
the PC9 parental cell line and of drug-
tolerant persisters and expanded per-
sisters. They noted a highly nonrandom 
distribution of differentially expressed 
genes along chromosomes, pointing to 
global chromatin alterations in the drug-
tolerant expanded persister population. 
One gene showing significant elevated 
expression in both drug-tolerant per-
sisters and expanded persisters was 
KDM5A encoding a histone demethy-
lase. This could explain the observed 
reduction in H3K4 methylation in these 
drug-resistant cell populations. KDM5A 
appears to be critical for acquiring the 
resistance phenotype as knockdown 
of this histone demethylase reduced 
the generation of drug-tolerant persist-
ers and expanded persisters from the 
PC9 parental cell line. Msc1, the yeast 
ortholog of KDM5A, is known to reduce 
H3K14 acetylation (Ahmed et al., 2004), 
and acetylation of H3K14 appeared to 
be decreased in drug-tolerant persist-
ers and expanded persisters, 
probably through the asso-
ciation of KDM5A with his-
tone deacetylases (HDACs) 
(Klose et al., 2007). So, the 
authors next tested the 
effects of HDAC inhibitors on 
the parental PC9 tumor cells 
as well as the drug-tolerant 
(expanded) persisters. Sur-
prisingly, HDAC inhibitors 
caused the rapid death of 
drug-tolerant persisters and 
expanded persisters but not 
the PC9 parental cell line 
(Figure 1). Cell death was 
associated with an altered 
DNA-damage response, as 
indicated by phosphorylation 
of the histone variant H2AX 
(γH2AX) in the drug-tolerant 
persister and expanded per-
sister cells but not in parental 
cells treated with an HDAC 
inhibitor. The mechanistic 
basis for the DNA-damage 
response of the persister 
and expanded persister cells 
after HDAC inhibitor treat-
ment is unclear, and the kill-
ing of these cells compared 
with the killing of PC9 paren-
tal cells by erlotinib seems 
to occur through a different 
mechanism.
The investigators set out to 
identify other compounds in 
addition to HDAC inhibitors 
that could prevent the devel-
opment of drug resistance. 
They pinpointed a selective 
inhibitor of the IGF-1 recep-
tor, AEW541. IGF-1 recep-
tor signaling is required for 
the induction of drug toler-
ance, and its inhibition leads 
to a substantial reduction in 
KDM5A expression, indicat-
ing that IGF-1 receptor sig-
naling likely results in chro-
matin modifications mediated 
by KDM5A. Although synergy between 
cytotoxic drugs and chromatin-modifying 
drugs has been reported (Camphausen 
and Tofilon, 2007), this is the first study 
to connect inhibition of HDACs with 
“reversible drug resistance.” Although 
future work will undoubtedly reveal the 
genes that confer drug resistance in 
response to KDM5A-mediated chroma-
tin modifications, the work described by 
Sharma et al. elucidates an important 
pathway that operates in the emergence 
of drug-tolerant persisters and expanded 
persisters.
Interestingly, when PC9 
parental cells were treated with 
both erlotinib and AEW541, a 
small number of drug-tolerant 
expanded persister cells car-
rying the EGFR T790M muta-
tion eventually emerged. Thus, 
under this drug regi men, 
genetic mutations became the 
preponderant mechanism of 
drug resistance. The fact that 
the EGFR T790M mutation is 
often found in cancer patients 
treated with erlotinib (Engelman 
and Jänne, 2008) indicates 
that in vivo “reversible” drug 
resistance is not a substitute 
for mutational mechanisms of 
drug resistance. However, the 
mutational stress imposed on 
cells exhibiting “reversible” 
drug resistance could facilitate 
the generation of hard-wired 
drug resistance mutations.
The ramifications of the 
work of Settleman and col-
leagues could be substantial. 
The prevention of “reversible” 
drug resistance by inhibitors of 
HDACs or IGF-1 receptor sig-
naling is intriguing, as it might 
provide a more effective way 
to treat tumors. The authors 
report that they have already 
initiated a clinical trial in which 
patients with non-small cell 
lung cancer are treated with a 
combination of erlotinib and a 
chromatin-modifying agent. 
However, rare tumor cells 
with EGFR mutations (or MET 
amplification) causing erlotinib 
resistance might still survive 
and cause cancer relapse. To 
eliminate such pre-existing 
erlotinib-resistant tumor cells, 
treatment with cisplatin and 
HDAC (or IGF-1 receptor) 
inhibitors, followed by erlotinib 
and HDAC (or IGF-1 receptor) 
inhibitors, could be considered. 
This would kill rare genetically resistant 
tumor cells harboring any erlotinib-resis-
tant mutations that were already present 
in the tumor prior to treatment. Time will 
tell whether these exciting observations 
that appear common in vitro also apply to 
real tumors in real people.
Figure 1. Drug Resistance in Lung Tumor Cells
A population of non-small cell lung tumor cells (PC9 parental cancer cell line), 
carrying the activating mutation EGFRdel19, consists of a heterogeneous mix 
of drug-sensitive cells (blue), nongenetic, drug-tolerant persisters (DTP, red), 
and possibly spurious tumor cells carrying the secondary T790M mutation 
in the epidermal growth factor receptor (EGFRT790M mutants; yellow). Upon 
treatment with the targeted drug erlotinib, the majority of the tumor popula-
tion is eradicated, but drug-tolerant persisters (red) survive and expand to 
generate drug-tolerant expanded persisters (DTEP, purple). DTP and DTEP 
are characterized by increased phosphorylation of the IGF-1 receptor (IGF-
1R), increased expression of the histone demethylase KDM5A, reduced H3K4 
methylation, and reduced H3K14 acetylation. Drug resistance of DTEP tumor 
cells is reversible as passaging these cells in the absence of erlotinib results 
in the emergence of a drug-sensitive heterogeneous tumor cell population. 
Treatment with chromatin-modifying drugs such as HDAC inhibitors elimi-
nates DTPs and DTEPs but does not kill the vast majority of the PC9 parental 
tumor cell population. Concomitant treatment with erlotinib and HDAC inhibi-
tors or IGF-1 receptor inhibitors results in effective ablation of drug-tolerant 
persisters thereby abrogating nongenetic drug resistance. Tumor cells surviv-
ing this treatment (yellow) have acquired genetic resistance due to secondary 
mutations (e.g., the T790M mutation) in EGFR.Cell 141, April 2, 2010 ©2010 Elsevier Inc. 19
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The p120 catenin (p120) protein cel-
ebrates its 21st birthday in the spring 
of 2010. Described initially as a sub-
strate of Src (Reynolds et al., 1989), 
p120 has emerged as a master regula-
tor of cadherin retention and stability 
at the cell surface (Davis et al., 2003; 
Xiao et al., 2003). The classical cad-
herin family of receptors (which has 26 
members in humans) is widely consid-
ered to be the most important of the 
cell-cell adhesion proteins in eukary-
otes. Cadherins essentially compete 
at the cell surface for interaction with a 
limited pool of p120; if p120 is unavail-
able, unbound cadherins are removed 
from the cell surface for destruction or 
recycling (for review, see Reynolds and 
Roczniak-Ferguson, 2004). This sta-
bilization effect by p120 clearly stems 
from its direct interaction with the cyto-
plasmic region of cadherin, but how 
this interaction is modulated to control 
cell adhesion is unclear. In this issue 
of Cell, Ishiyama et al. (2010) present 
the crystal structure of p120 in com-
plex with a fragment of cadherin; this 
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p120 might influence the stability and 
function of cadherin in cell-cell adhe-
sion complexes.
Cadherins are homophillic cell-cell 
adhesion receptors with essential roles 
in development, tissue morphogenesis, 
and cancer (Takeichi, 1995). Epithelial 
cadherin (E-cadherin) is the major cell-
cell adhesion molecule in most epithe-
lial tissues and is widely regarded as a 
master organizer of the epithelial phe-
notype. In most types of carcinoma, the 
downregulation of E-cadherin is closely 
linked to the emergence of metastasis 
and poor prognosis for patients.
β-catenin and p120 are key regu-
lators of E-cadherin. Both proteins 
are armadillo repeat domain proteins 
(Reynolds et al., 1992), which bind 
directly to the cytoplasmic domain of 
cadherin (Reynolds et al., 1994) (Figure 
1): β-catenin interacts with the catenin 
binding domain at the C-terminal end, 
and p120 catenin interacts with the jux-
tamembrane domain, which comprises 
?40 amino acids at the N-terminal end. 
It is believed that the binding of p120 
to the juxtamembrane domain of cad-
atenin’s  
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(2010). Cell, this issue.herin blocks factors such as the ubiq-
uitin ligase Hakai and components of 
the endocytic machinery, which tag 
and target cadherin for destruction and 
internalization. β-catenin also interacts 
with α-catenin, and together they mod-
ulate interactions with the underlying 
actin cytoskeleton (Figure 1).
With the p120/E-cadherin crystal 
structure presented by Ishiyama et al. 
(2010), all core components of the cad-
herin complex are now available at high 
resolution (2.4 to 2.8 Å), and it is pos-
sible to assemble in silico a complete 
cadherin complex from the molecu-
larly defined components (Figure 1, left 
panel). The resulting model nicely illus-
trates how the short polypeptide tail 
of the cadherin cytoplasmic domain, 
surprisingly, can anchor p120 and 
β-catenin simultaneously, even though 
each of these proteins is more than ten 
times the size of the cadherin fragment. 
The otherwise unstructured tail threads 
across and through the two catenins 
as if they were giant beads on a string, 
which would be a perfect analogy if 
not for the exquisitely choreographed 
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ce retention of cadherin. In this 
p120 in complex with cadherin, 
ing sophisticated new tools for 
